# PRIOR AUTHORIZATION CRITERIA

## BRAND NAME\* (generic)

# VIMPAT (lacosamide)

# Status: CVS Caremark Criteria Type: Initial Prior Authorization

Ref # 497-A

\* Drugs that are listed in the target drug box include both brand and generic and all dosages forms and strengths unless otherwise stated

## FDA-APPROVED INDICATIONS

Vimpat is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

As the safety of Vimpat injection in pediatric patients has not been established, Vimpat injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).

### **COVERAGE CRITERIA**

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of partial-onset seizures
  - AND
  - The request is for the injectable formulation in a patient 17 years of age or older OR
  - The request is for a non-injectable formulation in a patient 4 years of age or older

### RATIONALE

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Vimpat is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of Vimpat injections in pediatric patients has not been established, Vimpat injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).<sup>1-3</sup>

### REFERENCES

- 1. Vimpat [package insert]. Smyma, GA: UCB, Inc; November 2017.
- 2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.;
- http://online.lexi.com/lco/action/index/dataset/complete\_ashp [available with subscription]. Accessed November 2017.
  Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed November 2017.

| Written by:   | UM Development (SE)  |
|---------------|--|
| Date written: | 12/2009  |
| Revised:      | UM Development (KD) 04/2010 (CAS Adapted); (JK) 06/2011; (TM) 06/2012; (NB) 10/2012 (extended duration); (TM) 05/2013;     |
|               | (CT) 05/2014, 09/2014 (added new indication); (CF) 05/2015; (MS) 05/2016 (no clinical changes); (CT) 05/2017 (no clinical  |
|               | changes); (DS) 11/2017 (update to indication)  |
| Reviewed:     | Medical Affairs (WLF) 12/2009, 1/2010; (KP) 06/2011, 06/2012, 10/2012; DC) 05/2013; (LMS) 05/2014; (SES) 09/2014; (DNC)    |
|               | 05/2015; (LMS) 11/2017   |
|               | External Review: 6/2009 (P&T recommendations added 1/2010), 10/2010, 10/2011, 10/2012, 10/2013, 09/2014, 10/2015, 10/2016, |
|               | 10/2017  |
|               |  |

Vimpat 497-A 05-2017 (2).doc

©2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.



| CRITERIA FOR APPROVAL |  |     |    |  |  |  |
|-----------------------|--|-----|----|--|--|--|
| 1                     | Is the request for the injectable formulation of Vimpat (lacosamide)?<br>[If no, then skip to question 3.]   | Yes | No |  |  |  |
| 2                     | Is the requested drug being prescribed for the treatment of partial-onset seizures in a patient 17 years of age or older?<br>[No further questions.] | Yes | No |  |  |  |
| 3                     | Is the requested drug being prescribed for the treatment of partial-onset seizures in a patient 4 years of age or older?                             | Yes | No |  |  |  |

| Mapping Instructions |                       |         |  |  |  |  |
|----------------------|-----------------------|---------|--|--|--|--|
|                      | Yes                   | No      | DENIAL REASONS – DO NOT USE FOR MEDICARE PART D  |  |  |  |
| 1.                   | Go to 2               | Go to 3 |  |  |  |  |
| 2.                   | Approve, 36<br>months | Deny    | Your plan covers this drug when you meet all of these conditions:<br>- You are 17 years of age or older<br>- You have partial-onset seizures<br>Your use of this drug does not meet the requirements. This is based on<br>the information we have. |  |  |  |
| 3.                   | Approve, 36<br>months | Deny    | Your plan covers this drug when you meet all of these conditions:<br>- You are 4 years of age or older<br>- You have partial-onset seizures<br>Your use of this drug does not meet the requirements. This is based on<br>the information we have.  |  |  |  |

Vimpat 497-A 05-2017 (2).doc

©2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

